## Ryan J O Dowling

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4972407/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Metformin Is an AMP Kinase–Dependent Growth Inhibitor for Breast Cancer Cells. Cancer Research, 2006, 66, 10269-10273.	0.9	972
2	Metformin Inhibits Mammalian Target of Rapamycin–Dependent Translation Initiation in Breast Cancer Cells. Cancer Research, 2007, 67, 10804-10812.	0.9	845
3	mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs. Science, 2010, 328, 1172-1176.	12.6	624
4	Dissecting the role of mTOR: Lessons from mTOR inhibitors. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2010, 1804, 433-439.	2.3	389
5	Nuclear PTEN Controls DNA Repair and Sensitivity to Genotoxic Stress. Science, 2013, 341, 395-399.	12.6	351
6	Understanding the benefit of metformin use in cancer treatment. BMC Medicine, 2011, 9, 33.	5.5	324
7	Metformin in cancer: translational challenges. Journal of Molecular Endocrinology, 2012, 48, R31-R43.	2.5	295
8	Translational control of the innate immune response through IRF-7. Nature, 2008, 452, 323-328.	27.8	275
9	The Effects of Adiponectin and Metformin on Prostate and Colon Neoplasia Involve Activation of AMP-Activated Protein Kinase. Cancer Prevention Research, 2008, 1, 369-375.	1.5	266
10	Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Research and Treatment, 2012, 135, 821-830.	2.5	213
11	Translational control of the activation of transcription factor NF-κB and production of type I interferon by phosphorylation of the translation factor eIF4E. Nature Immunology, 2012, 13, 543-550.	14.5	114
12	Metformin Pharmacokinetics in Mouse Tumors: Implications for Human Therapy. Cell Metabolism, 2016, 23, 567-568.	16.2	105
13	p53-Dependent Translational Control of Senescence and Transformation via 4E-BPs. Cancer Cell, 2009, 16, 439-446.	16.8	104
14	Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Research, 2015, 17, 32.	5.0	92
15	Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial. Breast Cancer Research and Treatment, 2015, 150, 149-155.	2.5	77
16	Association of Obesity-Related Metabolic Disruptions With Cancer Risk and Outcome. Journal of Clinical Oncology, 2016, 34, 4249-4255.	1.6	77
17	A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. Breast, 2019, 48, 17-23.	2.2	73
18	Impact of a Pre-Operative Exercise Intervention on Breast Cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study. Clinical Cancer Research, 2019, 25, 5398-5406.	7.0	58

RYAN J O DOWLING

#	Article	IF	CITATIONS
19	Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy. BioDrugs, 2009, 23, 77-91.	4.6	45
20	The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32. Journal of the National Cancer Institute, 2021, 113, 192-198.	6.3	24
21	A collection of caged compounds for probing roles of local translation in neurobiology. Bioorganic and Medicinal Chemistry, 2010, 18, 7746-7752.	3.0	20
22	Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial. Npj Breast Cancer, 2021, 7, 74.	5.2	16
23	Gene-expression changes induced by Feline immunodeficiency virus infection differ in epithelial cells and lymphocytes. Journal of General Virology, 2005, 86, 2239-2248.	2.9	12
24	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI Cancer Spectrum, 2019, 3, pkz049.	2.9	11
25	Association of Metabolic, Inflammatory, and Tumor Markers With Circulating Tumor Cells in Metastatic Breast Cancer. JNCI Cancer Spectrum, 2018, 2, pky028.	2.9	10
26	Cancer Antigen 15-3/Mucin 1â€,Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo. JNCI Cancer Spectrum, 2021, 5, pkab066.	2.9	5
27	Fundamental Pathways in Breast Cancer 1: Signaling from the Membrane. , 2017, , 3-12.		1
28	Metformin and Exercise in Cancer: Better Together. JNCI Cancer Spectrum, 2020, 4, pkz097.	2.9	1